Gain Therapeutics (GANX) Income from Non-Controlling Interests (2020 - 2022)

Gain Therapeutics' Income from Non-Controlling Interests history runs 3 years deep, the most recent figure standing at $7468.0 for Q1 2022.

• In Q1 2022, Income from Non-Controlling Interests rose 41.73% year-over-year to $7468.0; the TTM figure through Dec 2022 stood at $7468.0 (down 75.96% YoY), while the FY2022 annual figure was $7468.0, down 75.96% from the prior year.
• Income from Non-Controlling Interests for Q1 2022 stood at $7468.0, up from $6867.0 in the prior quarter.
• The five-year high for Income from Non-Controlling Interests was $11374.0 in Q3 2021, with the low at $5269.0 in Q1 2021.
• The 3-year median for Income from Non-Controlling Interests is $6867.0 (2021), against an average of $7490.6.
• Peak annual rise in Income from Non-Controlling Interests reached 69.86% in 2021, while the deepest fall reached 24.86% in 2021.
• Gain Therapeutics' Income from Non-Controlling Interests stood at $9139.0 in 2020, then dropped by 24.86% to $6867.0 in 2021, then advanced by 8.75% to $7468.0 in 2022.
• Business Quant data shows GANX's Income from Non-Controlling Interests at $7468.0 in Q1 2022, $6867.0 in Q4 2021, and $11374.0 in Q3 2021.